MiR-34a Functions As a Tumor Suppressor Modulating EGFR in Glioblastoma Multiforme
Overview
Affiliations
Chromosome 1p36.23 is frequently deleted in glioblastoma multiforme (GBM). miR-34a localizes in this region. Our experiments found that miR-34a was often deleted and epidermal growth factor receptor (EGFR) was frequently amplified in genomic DNA of 55 GBMs using single-nucleotide polymorphism DNA microarray. Notably, we found that the mean survival time was significantly shortened for patients whose GBMs had both EGFR amplification and miR-34a deletion. Expression of miR-34a was significantly lower in GBM samples compared with normal brain tissue. Forced expression of miR-34a in GBM cells decreased their ability to migrate and profoundly decreased their levels of cyclin-A1, -B1, -D1, and -D3, as well as cyclin-dependent kinase and increased expression of cyclin kinase inhibitor proteins (p21, p27). Also, human GBM cells (U251) stable overexpressing mir-34a formed smaller tumors when growing as xenografts in immunodeficient mice compared with wild-type U251 GBM cells. Furthermore, the protein expression of EGFR decreased in the cells with forced overexpression of miR-34a. Additional studies showed that mir-34a targeted Yin Yang-1 (YY1) and YY1 is a transcription factor that can stimulate the expression of EGFR. Thus, our data suggest that miR-34a acts as a tumor suppressor by inhibiting growth of GBM cells in vitro and in vivo associated with moderating the expression of cell-cycle proteins and EGFR. Moreover, we discovered for the first time that both deletion of miR-34a and amplification of EGFR were associated with significantly decreased overall survival of GBM patients.
Fekrirad Z, Gharedaghi M, Saadatpour F, Molabashi Z, Rezayof A, Korourian A Heliyon. 2024; 10(17):e37041.
PMID: 39286083 PMC: 11403485. DOI: 10.1016/j.heliyon.2024.e37041.
Ordonez-Rubiano E, Rincon-Arias N, Espinosa S, Shelton W, Salazar A, Combita A Curr Res Pharmacol Drug Discov. 2024; 7:100193.
PMID: 39055532 PMC: 11268206. DOI: 10.1016/j.crphar.2024.100193.
Glioblastoma Therapy: Past, Present and Future.
Obrador E, Moreno-Murciano P, Oriol-Caballo M, Lopez-Blanch R, Pineda B, Gutierrez-Arroyo J Int J Mol Sci. 2024; 25(5).
PMID: 38473776 PMC: 10931797. DOI: 10.3390/ijms25052529.
Use of microRNAs as Diagnostic, Prognostic, and Therapeutic Tools for Glioblastoma.
Valle-Garcia D, la Cruz V, Flores I, Salazar A, Pineda B, Meza-Sosa K Int J Mol Sci. 2024; 25(5).
PMID: 38473710 PMC: 10931459. DOI: 10.3390/ijms25052464.
MicroRNA-34a-Dependent Attenuation of Angiogenesis in Right Ventricular Failure.
Reddy S, Hu D, Zhao M, Ichimura S, Barnes E, Cornfield D J Am Heart Assoc. 2024; 13(3):e029427.
PMID: 38293915 PMC: 11056115. DOI: 10.1161/JAHA.123.029427.